The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC-UNC) is a team of scientists dedicated to discovering and sharing selective, small molecule inhibitors of protein kinases. Their work aims to expand drug discovery across this important class of disease-relevant proteins and help speed the creation of new medicines for patients.
The UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill houses the first U.S. site of the SGC, a public-private target discovery consortium that catalyzes research in new areas of human biology and drug discovery. The SGC-UNC mission is to:
- A public-private partnership to unlock the untargeted kinome. Nature Chemical Biology Read more
- Seeding Collaborations to Advance Kinase Science with the GSK Published Kinase Inhibitor Set (PKIS) Curr. Top. Med. Chem. Read more
- Open access chemical and clinical probes to support drug discovery. Nature Chemical Biology Read more
- The promise and peril of chemical probes. Nat. Chem Biol. Read more
Coming soon : "Targeting the untargeted kinome: the GSK published kinase inhibitor set." Nat. Biotechnol.